FDA approves oral, fixed-dose therapeutic for adults with ALS

The FDA has approved Relyvrio, an oral, fixed-dose combination therapy for the treatment of adults with ALS, Amylyx Pharmaceuticals Inc. announced in a press release.
According to the release, Relyvrio (sodium phenylbutyrate and taurursodiol, Amylyx) significantly slowed the loss of physical function in people with ALS in a randomized, placebo-controlled clinical trial, results of which have been published in several medical journals. ALS currently affects approximately 29,000 Americans, the release stated, and more than 90% of adults with ALS have sporadic disease, with no family history.
“The

The FDA has approved Relyvrio, an oral, fixed-dose combination therapy for the treatment of adults with ALS, Amylyx Pharmaceuticals Inc. announced in a press release.
According to the release, Relyvrio (sodium phenylbutyrate and taurursodiol, Amylyx) significantly slowed the loss of physical function in people with ALS in a randomized, placebo-controlled clinical trial, results of which have been published in several medical journals. ALS currently affects approximately 29,000 Americans, the release stated, and more than 90% of adults with ALS have sporadic disease, with no family history.
“The